BEIJING (Reuters) - Different efficacy results for a Chinese COVID-19 vaccine released separately in China and in United Arab Emirates are both real and valid, an executive at China National Biotec Group (CNBG) told state media.
China approved its first COVID-19 vaccine for general public use on Thursday, a shot developed by an affiliate to state-backed Sinopharm, after the developer said the vaccine showed 79.34% efficacy based on an interim analysis of late-stage clinical trials.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
